Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant I...
Georgina V. Long, I. Pires da Silva, Kristen A. Perry et al.· Nature Medicine· 0 citations
PURPOSE
This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors....
L. Siu, Omid Hamid, Reva Schneider et al.· Clinical Cancer Research· 0 citations
D dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab were tolerated and preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.
B. Carneiro, Thomas U. Marron, Dmitry Zamarin et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.